A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

NCT01085422 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: ABT-888
DRUG: temozolomide

Sponsor

AbbVie (prior sponsor, Abbott)

Collaborators

[object Object]